Literature DB >> 9576579

Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration.

D M Adcock1, D C Kressin, R A Marlar.   

Abstract

We evaluated the effect of sample volume and citrate concentration on results of routine coagulation assays (prothrombin time [PT] and activated partial thromboplastin time [APTT]). The study was performed on samples obtained from healthy persons and patients receiving oral anticoagulant therapy. Standard evacuated tubes (3.2% and 3.8% sodium citrate) were filled to varying total sample volumes ranging from 3.0 to 5.0 mL, and results of routine coagulation tests were compared. Underfilling may significantly affect the APTT and PT, resulting in artifactual prolongation of results. This effect is most pronounced in samples drawn into 3.8% citrate. By using 3.8% citrate, there is a statistically significant difference in the results of PT assays in the samples less than 80% filled compared with those that are 100% filled. For APTT assays performed on samples drawn into 3.8% citrate, a statistical difference occurred at less than 90% filled. This effect was less pronounced when samples were drawn into 3.2% sodium citrate. We found no statistically significant difference in PT results from a 3.2% citrate tube between fill volumes of 60% and 100% and none for APTT results between fill volumes of 70% and 100%. This study further supports the recommendation to use 3.2% sodium citrate concentration, because 60% of the optimum filled volume for PT and 70% of the optimum filled volume for APTT are acceptable.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576579     DOI: 10.1093/ajcp/109.5.595

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Clotting screen requests in pediatrics.

Authors:  Jecko Thachil; Gail Ann Whitehead
Journal:  Indian J Pediatr       Date:  2011-12-15       Impact factor: 1.967

2.  Effect of anticoagulant adjustment on prothrombin time test using two different PT reagents in patients with elevated hematocrit.

Authors:  Vanessa M Silva; Denise C Rezende; Edna S Garcia; Cyrillo Cavalheiro; Celia C Strunz
Journal:  Pract Lab Med       Date:  2020-10-17

3.  Influence of blood collection systems on coagulation tests.

Authors:  Soner Yavaş; Selime Ayaz; S Kenan Köse; Fatma Ulus; A Tulga Ulus
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

4.  From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.

Authors:  Jori E May; Rance Chad Siniard; Laura J Taylor; Marisa B Marques; Radhika Gangaraju
Journal:  Am J Clin Pathol       Date:  2022-03-03       Impact factor: 5.400

Review 5.  Coagulation assessment with the new generation of oral anticoagulants.

Authors:  Charles V Pollack
Journal:  Emerg Med J       Date:  2015-05-18       Impact factor: 2.740

Review 6.  Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories.

Authors:  A Magnette; M Chatelain; B Chatelain; H Ten Cate; F Mullier
Journal:  Thromb J       Date:  2016-12-12

7.  Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of Low Volume Sample Analysis.

Authors:  Jillian A Condrey; Timothy Flietstra; Kaitlyn M Nestor; Elizabeth L Schlosser; JoAnn D Coleman-McCray; Sarah C Genzer; Stephen R Welch; Jessica R Spengler
Journal:  Microorganisms       Date:  2020-07-27

8.  Prothrombin Time and Activated Partial Thromboplastin Time Testing: A Comparative Effectiveness Study in a Million-Patient Sample.

Authors:  Manu N Capoor; Jerry L Stonemetz; John C Baird; Fahad S Ahmed; Ahsan Awan; Christof Birkenmaier; Mario A Inchiosa; Steven K Magid; Kathryn McGoldrick; Ernesto Molmenti; Sajjad Naqvi; Stephen D Parker; S M Pothula; Aryeh Shander; R Grant Steen; Michael K Urban; Judith Wall; Vincent A Fischetti
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

Review 9.  Clinical Scenarios for Discordant Anti-Xa.

Authors:  Jesus Vera-Aguilera; Hindi Yousef; Diego Beltran-Melgarejo; Teng Hugh Teng; Ramos Jan; Mary Mok; Carlos Vera-Aguilera; Eduardo Moreno-Aguilera
Journal:  Adv Hematol       Date:  2016-05-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.